Article
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
HIV medicine - 1 Aug 2017
Poveda E, Hernández-Quero J, Pérez-Elías M J, Ribas M A, Martínez-Madrid O J, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R
Abstract excerpt
OBJECTIVES: Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. METHODS: PROTEST was a phase 4, prospective, single-arm clinical trial...
Topics
- Adult
- CCR5 Receptor Antagonists
- Cyclohexanes
- DNA, Viral
- Female
- Genotype
- Genotyping Techniques
- HIV-1
- Humans
- Maintenance Chemotherapy
